Quality and Patient Safety – Neuro Battle against Deep Vein Thrombosis
Read the Magazine in PDF
Abstract
This article highlights the neurobattle against DVT in neurosurgical cases. It emphasizes the importance of timely treatment and prophylaxis to prevent fatal complications. Challenges in insurance coverage for DVT prophylaxis are also discussed. The study proposes a Neuro One Prophylaxis DVT Protocol Chart to improve patient outcomes and raise awareness about DVT’s seriousness.
Introduction
DVT is a common condition that we encounter daily, but its severity has reached a worrisome level. If not treated promptly, it can lead to pulmonary embolism and, unfortunately, even patient fatalities. The venous system, particularly the large veins, is affected by clot formation, leading to venous stasis and hypercoagulability.
In this article, we will discuss the neuro-battle against DVT, highlighting the incidence of DVT in neurosurgical cases and the steps taken to prevent it. We will also touch upon the challenges faced in getting DVT prophylaxis covered by insurance.
DVT in Neurosurgical Cases
In our neurosurgical cases, the incidence of DVT has been significant, ranging from 7.9% to 29%. Even though our surgeries have been successful, we have still lost patients due to DVT and subsequent pulmonary embolism.
The highest risk of DVT is observed in patients with brain tumors, craniotomies, and head injuries, especially those with cerebral metastases and gliomas.
The Study
To address this issue, we conducted a thorough analysis of 543 patients over the course of a year (from January 2021 to December 2021). We implemented a D-dimer screening for medical and surgical cases on admission, and low molecular weight heparin was administered to 5190 patients with continuous monitoring. Additionally, all patients, except for those with specific complications, were mobilized on the first postoperative day.
Neuro One Prophylaxis DVT Prophylaxis
Based on our experience, we developed a Neuro One Prophylaxis DVT Protocol Chart to monitor and manage DVT cases in neurological settings effectively. Raising awareness about DVT’s profound implications is essential, as it is a global health concern.
We estimate that 60,000 to 100,000 Americans die each year due to DVT, and one-third of the world’s population experiences recurrence within a decade.
However, one challenge we face is that medical insurance companies often need to fully cover DVT prophylaxis treatment, as they may not recognize venous diseases as severe conditions.
Therefore, it was appealing to the medical insurance community to reconsider their approach and acknowledge the gravity of DVT, as timely treatment can prevent fatal complications like pulmonary embolism.
Conclusion
The incidence of DVT in neurosurgical cases remains a significant concern. However, through the implementation of our Neuro One Prophylaxis DVT Protocol Chart, we have achieved a reduction in DVT cases to less than 1%. Let us all join the neurobattle against DVT and work together to create awareness and improve patient outcomes. Thank you for your attention.
FAQs
Q. Why were all patients put on Heparin and not monitored on DVT rescore?
A. All patients were put on Heparin, but they were not monitored for DVT scores or anything. This may be because of certain inclusion and exclusion criteria that segregated patients into different categories. Patients who did not fit into the checklist were scrutinized to make a final checklist that could cater to at least 90% of the population.
Q. Why wasn’t any data presented during the study period of one year?
A. All patients were put on Heparin, but they were not monitored for DVT scores or anything. This may be because of certain inclusion and exclusion criteria that segregated patients into different categories. Patients who did not fit into the checklist were scrutinized to make a final checklist that could cater to at least 90% of the population.
Q. How was the validation of data done during the study?
A. The researchers used a checklist to validate the data during the study. They started working on the checklist and scrutinized different types of patients who did not fit into the checklist.
After scrutinizing and scrutinizing, they made a checklist that could cater to around 90% of the population. However, a checklist may not be 100% validated.
